<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418324</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2016-16-POSADAS-TRC105</org_study_id>
    <nct_id>NCT03418324</nct_id>
  </id_info>
  <brief_title>Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy</brief_title>
  <official_title>A Phase 2 Study of TRC105 (Anti-endoglin Antibody) With Abiraterone and With Enzalutamide in Metastatic, Castration Resistant Prostate Cancer Patients Progressing on Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to measure the clinical benefit of TRC105 in combination&#xD;
      with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients&#xD;
      who are taking either abiraterone or enzalutamide and showing signs of biochemical&#xD;
      progression without radiographic progression. A patient who is progressing on AR-therapy will&#xD;
      continue the same AR-therapy on study with the addition of TRC105. The two arms will accrue&#xD;
      in parallel and independently.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open-label study of TRC105 (anti-endoglin antibody) in combination with&#xD;
      abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who&#xD;
      are taking either abiraterone or enzalutamide and showing signs of biochemical progression&#xD;
      without radiographic progression. A patient who is progressing on AR-therapy will continue&#xD;
      the same AR-therapy on study with the addition of TRC105. The two arms will accrue in&#xD;
      parallel and independently.&#xD;
&#xD;
      There will be a 2-week washout of the active AR-targeted therapy prior to initiation of&#xD;
      combination therapy. Tumor response should be assessed at a frequency of 8 weeks by CT/MRI&#xD;
      chest, abdomen and pelvis as well as bone scan. Patients may continue on therapy until&#xD;
      radiographic progression by RECIST 1.1 or PCWG3 criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Actual">November 6, 2019</completion_date>
  <primary_completion_date type="Actual">November 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bayesian design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Clinical Benefit</measure>
    <time_frame>Through study completion, average 24 months</time_frame>
    <description>Number of participants with stabilization of disease for at least 2 months or disease improvement at any time from start of combination therapy by radiographic and/or biochemical criteria through treatment completion up to an estimated period of 24 months&#xD;
radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria&#xD;
Biochemical response will be defined by PCWG3 criteria&#xD;
Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events From TRC105 and Abiraterone or Enzalutamide</measure>
    <time_frame>4 months</time_frame>
    <description>Number of participants with grade 3/4 Adverse Events Related to investigational therapy as assessed Using CTCAE (v.4) up to 4 months from treatment initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time (in Months) from treatment initiation to radiographic and clinical progression over study duration (estimated 24 months)&#xD;
- radiographic criteria measured by RECIST 1.1 [Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions plus an absolute increase of at least 5 mm, taking as reference the smallest sum recorded since the start of study]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit at Two Months</measure>
    <time_frame>2 months</time_frame>
    <description>Proportion of participants with stabilization of disease for two months or disease improvement at anytime from start of combination therapy to two months by radiographic and/or biochemical criteria&#xD;
radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria&#xD;
Biochemical response will be defined by PCWG3 criteria&#xD;
Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit at Four Months</measure>
    <time_frame>4 months</time_frame>
    <description>Proportion of participants with stabilization of disease for at least 4 months or disease improvement at anytime from start of combination therapy to four months by radiographic and/or biochemical criteria&#xD;
radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria&#xD;
Biochemical response will be defined by PCWG3 criteria&#xD;
Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit From PSA Serum Concentration (2 Months)</measure>
    <time_frame>2 months</time_frame>
    <description>Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit From PSA Serum Concentration (4 Months)</measure>
    <time_frame>4 months</time_frame>
    <description>Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: TRC105 + Abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: TRC105 + Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC105</intervention_name>
    <description>Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks</description>
    <arm_group_label>Arm A: TRC105 + Abiraterone</arm_group_label>
    <arm_group_label>Arm E: TRC105 + Enzalutamide</arm_group_label>
    <other_name>Carotuximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
    <arm_group_label>Arm A: TRC105 + Abiraterone</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
    <arm_group_label>Arm E: TRC105 + Enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of metastatic, castration-resistant prostate cancer with rising PSA on either&#xD;
             abiraterone or enzalutamide&#xD;
&#xD;
               -  PSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least&#xD;
                  2 separate occasions greater than 1 week apart while on either abiraterone or&#xD;
                  enzalutamide&#xD;
&#xD;
               -  If there is a drop in serum PSA after the first rise, and the patient has another&#xD;
                  PSA rise which is greater than the first, the patient will still be considered&#xD;
                  eligible.&#xD;
&#xD;
          2. ECOG 0-2&#xD;
&#xD;
          3. Resolution of adverse events results as described below.&#xD;
&#xD;
               -  Laboratory abnormalities must meet values specified below in criteria #4&#xD;
&#xD;
               -  If the patient's most recent line of therapy is treatment with abiraterone or&#xD;
                  enzalutamide, then all adverse events must be resolved to Grade 2 or better&#xD;
&#xD;
               -  If the most recent line of therapy is any other treatment for mCRPC then all&#xD;
                  Adverse events must be resolved to grade 1 or better, with the exception of&#xD;
                  fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2)&#xD;
&#xD;
          4. Adequate organ function defined by:&#xD;
&#xD;
               -  AST and ALT &lt; 2.5 x ULN&#xD;
&#xD;
               -  Total serum bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
               -  Platelets &gt; 60,000&#xD;
&#xD;
               -  Hgb &gt; 8.5 g/dL&#xD;
&#xD;
               -  Serum Cr &lt;1.5 x ULN or a creatinine clearance &gt; 30.&#xD;
&#xD;
               -  INR ≤ 1.2 unless the patient is receiving a direct Factor Xa inhibitor or a&#xD;
                  direct thrombin inhibitor&#xD;
&#xD;
          5. Patients must be surgically sterile or must agree to use effective contraception&#xD;
             during the study and for 3 months following last dose of TRC105. The definition of&#xD;
             effective contraception will be based on the judgment of the Principal Investigator or&#xD;
             a designated associate. Abstinence from intercourse is an acceptable form of&#xD;
             contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-PSA producing prostate cancers- such as small cell prostate cancers or those&#xD;
             prostate cancers which exhibit radiographic progression without PSA rise&#xD;
&#xD;
          2. Inability to tolerate standard doses of abiraterone (1000 mg daily) or enzalutamide&#xD;
             (160 mg daily).&#xD;
&#xD;
          3. Other prior malignancy requiring active anticancer therapy&#xD;
&#xD;
          4. Prior exposure to TRC105 or any CD105 targeted antibody&#xD;
&#xD;
          5. Any major surgical procedure within 2 weeks of starting therapy&#xD;
&#xD;
          6. Uncontrolled chronic hypertension defined as sustained by systolic pressure (SBP) &gt;150&#xD;
             mmHg or diastolic pressure (DBP) &gt;90 despite optimal therapy.&#xD;
&#xD;
          7. Active bleeding or pathologic conditions that carries a high bleeding risk&#xD;
&#xD;
          8. Use of thrombolytics within 10 days prior to the first day of TRC105&#xD;
&#xD;
          9. Known hypersensitivity to Chinese hamster ovary products or other recombinant human,&#xD;
             chimeric, or humanized antibodies&#xD;
&#xD;
         10. A known diagnosis of Osler-Weber-Rendu syndrome&#xD;
&#xD;
         11. Ascites or pericardial or pleural effusion requiring external drainage procedures&#xD;
&#xD;
         12. History of untreated brain involvement with cancer, spinal cord compression, or&#xD;
             carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients&#xD;
             with radiated or resected lesions are permitted, provided the lesions are fully&#xD;
             treated and inactive, patients are asymptomatic, and no steroids have been&#xD;
             administered for at least 28 days. Imaging for CNS disease will not be required for&#xD;
             screening unless there is a history of a neurological finding such as new onset&#xD;
             weakness or numbness that cannot be explained by other medical history.&#xD;
&#xD;
         13. Acute cardiovascular event within the past 6 months. An acute cardiovascular event&#xD;
             will be defined as a myocardial infraction, NYHA Class II or worse congestive heart&#xD;
             failure, cerebrovascular accident, transient ischemic attack, arterial embolism,&#xD;
             pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or CABG.&#xD;
             Deep venous thrombosis within 6 months, unless the patient is anti-coagulated without&#xD;
             the use of warfarin for at least 2 weeks. In this situation, low molecular weight&#xD;
             heparin is preferred.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin Posadas, MD FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <results_first_submitted>October 30, 2020</results_first_submitted>
  <results_first_submitted_qc>December 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 30, 2020</results_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Edwin Posadas, MD</investigator_full_name>
    <investigator_title>Medical Director, Urologic Oncology Program</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Metastatic Prostate Cancer</keyword>
  <keyword>Castration Resistant Prostate Cancer</keyword>
  <keyword>Metastatic Castration Resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03418324/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study opened to accrual February 5, 2018 and the first patient on study March 5, 2018. As of November 6, 2019, 12 patients have been consented, 11 were enrolled, and 11 were off-treatment and off-study. Study closed to accrual on May 1, 2019, as drug manufacturer has limited drug supply without plans to increase production.</recruitment_details>
      <pre_assignment_details>Early accrual closure due to manufacturer's limited drug supply.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: TRC105 + Abiraterone</title>
          <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
        </group>
        <group group_id="P2">
          <title>Arm E: TRC105 + Enzalutamide</title>
          <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: TRC105 + Abiraterone</title>
          <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
        </group>
        <group group_id="B2">
          <title>Arm E: TRC105 + Enzalutamide</title>
          <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" lower_limit="74" upper_limit="79"/>
                    <measurement group_id="B2" value="72" lower_limit="57" upper_limit="73"/>
                    <measurement group_id="B3" value="72" lower_limit="57" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" spread="3.53"/>
                    <measurement group_id="B2" value="67.83" spread="6.97"/>
                    <measurement group_id="B3" value="70" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Clinical Benefit</title>
        <description>Number of participants with stabilization of disease for at least 2 months or disease improvement at any time from start of combination therapy by radiographic and/or biochemical criteria through treatment completion up to an estimated period of 24 months&#xD;
radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria&#xD;
Biochemical response will be defined by PCWG3 criteria&#xD;
Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria</description>
        <time_frame>Through study completion, average 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: TRC105 + Abiraterone</title>
            <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
          </group>
          <group group_id="O2">
            <title>Arm E: TRC105 + Enzalutamide</title>
            <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Clinical Benefit</title>
          <description>Number of participants with stabilization of disease for at least 2 months or disease improvement at any time from start of combination therapy by radiographic and/or biochemical criteria through treatment completion up to an estimated period of 24 months&#xD;
radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria&#xD;
Biochemical response will be defined by PCWG3 criteria&#xD;
Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Clinical Benefit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiographic Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biochemical Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stabilization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For this study, we are not comparing outcome measures between the two arms</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Binomial proportion (Clopper-Pearson exact confidence interval) for each arm</non_inferiority_desc>
            <param_type>Binomial proportion</param_type>
            <param_value>50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>98.7</ci_upper_limit>
            <estimate_desc>Estimated values reflects the percentage of participants with overall clinical benefit.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For this study, we are not comparing outcome measures between the two groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Binomial proportion (Clopper-Pearson exact confidence interval) for each arm</non_inferiority_desc>
            <param_type>Binomial proportion</param_type>
            <param_value>66.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.3</ci_lower_limit>
            <ci_upper_limit>95.7</ci_upper_limit>
            <estimate_desc>Estimated values reflects the percentage of participants with overall clinical benefit</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events From TRC105 and Abiraterone or Enzalutamide</title>
        <description>Number of participants with grade 3/4 Adverse Events Related to investigational therapy as assessed Using CTCAE (v.4) up to 4 months from treatment initiation.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: TRC105 + Abiraterone</title>
            <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
          </group>
          <group group_id="O2">
            <title>Arm E: TRC105 + Enzalutamide</title>
            <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events From TRC105 and Abiraterone or Enzalutamide</title>
          <description>Number of participants with grade 3/4 Adverse Events Related to investigational therapy as assessed Using CTCAE (v.4) up to 4 months from treatment initiation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Time (in Months) from treatment initiation to radiographic and clinical progression over study duration (estimated 24 months)&#xD;
- radiographic criteria measured by RECIST 1.1 [Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions plus an absolute increase of at least 5 mm, taking as reference the smallest sum recorded since the start of study]</description>
        <time_frame>24 months</time_frame>
        <population>Median progression free survival (months) (95% confidence interval). Not enough data (insufficient number of participants with events) to establish upper limit.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: TRC105 + Abiraterone</title>
            <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
          </group>
          <group group_id="O2">
            <title>Arm E: TRC105 + Enzalutamide</title>
            <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Time (in Months) from treatment initiation to radiographic and clinical progression over study duration (estimated 24 months)&#xD;
- radiographic criteria measured by RECIST 1.1 [Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions plus an absolute increase of at least 5 mm, taking as reference the smallest sum recorded since the start of study]</description>
          <population>Median progression free survival (months) (95% confidence interval). Not enough data (insufficient number of participants with events) to establish upper limit.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" lower_limit="1.64" upper_limit="NA">Not enough data (insufficient number of participants with events) to establish upper limit.</measurement>
                    <measurement group_id="O2" value="4.46" lower_limit="1.71" upper_limit="NA">Not enough data (insufficient number of participants with events) to establish upper limit.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit at Two Months</title>
        <description>Proportion of participants with stabilization of disease for two months or disease improvement at anytime from start of combination therapy to two months by radiographic and/or biochemical criteria&#xD;
radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria&#xD;
Biochemical response will be defined by PCWG3 criteria&#xD;
Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: TRC105 + Abiraterone</title>
            <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
          </group>
          <group group_id="O2">
            <title>Arm E: TRC105 + Enzalutamide</title>
            <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit at Two Months</title>
          <description>Proportion of participants with stabilization of disease for two months or disease improvement at anytime from start of combination therapy to two months by radiographic and/or biochemical criteria&#xD;
radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria&#xD;
Biochemical response will be defined by PCWG3 criteria&#xD;
Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Benefit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiographic Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biochemical Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stabilization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For this study, we are not comparing outcome measures between the two arms</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Binomial proportion (Clopper-Pearson exact confidence interval) for each arm.</non_inferiority_desc>
            <param_type>Binomial proportion</param_type>
            <param_value>50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>98.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For this study, we are not comparing outcome measures between the two arms.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Binomial proportion (Clopper-Pearson exact confidence interval) for each arm.</non_inferiority_desc>
            <param_type>Binomial proportion</param_type>
            <param_value>66.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.3</ci_lower_limit>
            <ci_upper_limit>95.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit at Four Months</title>
        <description>Proportion of participants with stabilization of disease for at least 4 months or disease improvement at anytime from start of combination therapy to four months by radiographic and/or biochemical criteria&#xD;
radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria&#xD;
Biochemical response will be defined by PCWG3 criteria&#xD;
Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: TRC105 + Abiraterone</title>
            <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
          </group>
          <group group_id="O2">
            <title>Arm E: TRC105 + Enzalutamide</title>
            <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit at Four Months</title>
          <description>Proportion of participants with stabilization of disease for at least 4 months or disease improvement at anytime from start of combination therapy to four months by radiographic and/or biochemical criteria&#xD;
radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria&#xD;
Biochemical response will be defined by PCWG3 criteria&#xD;
Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Benefit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiographic Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biochemical Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stabilization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For this study, we are not comparing outcome measures between the two arms.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Binomial proportion (Clopper-Pearson exact confidence interval) for each arm.</non_inferiority_desc>
            <param_type>Binomial proportion</param_type>
            <param_value>50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>98.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For this study, we are not comparing outcome measures between the two arms.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Binomial proportion (Clopper-Pearson exact confidence interval) for each arm.</non_inferiority_desc>
            <param_type>Binomial proportion</param_type>
            <param_value>50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.8</ci_lower_limit>
            <ci_upper_limit>88.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit From PSA Serum Concentration (2 Months)</title>
        <description>Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: TRC105 + Abiraterone</title>
            <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
          </group>
          <group group_id="O2">
            <title>Arm E: TRC105 + Enzalutamide</title>
            <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit From PSA Serum Concentration (2 Months)</title>
          <description>Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit From PSA Serum Concentration (4 Months)</title>
        <description>Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: TRC105 + Abiraterone</title>
            <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
          </group>
          <group group_id="O2">
            <title>Arm E: TRC105 + Enzalutamide</title>
            <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit From PSA Serum Concentration (4 Months)</title>
          <description>Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>3 patients consented to Arm A, but only 2 were considered evaluable (1 patient considered unevaluable per physician decision prior to treatment start). 8 patients consented to Arm E, but 6 were considered evaluable. Of the 2 patients not included in Arm E, 1 patient was deemed unevaluable by physician decision prior to starting study treatment, and the other died prior to starting study treatment. Therefore, this number is reflected in All-Cause Mortality, and differs from SAEs and Other.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: TRC105 + Abiraterone</title>
          <description>Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Abiraterone: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.</description>
        </group>
        <group group_id="E2">
          <title>Arm E: TRC105 + Enzalutamide</title>
          <description>Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide&#xD;
TRC105: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks&#xD;
Enzalutamide: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis (peri-mandibular)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia Hemoglobin (Hgb)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Redness sclera left eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vision decrease (binocular)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Guaiac + Stool</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Geographic Tongue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lip pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Generalized weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>MRSA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cauda equina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Right leg sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Recurrent laryngeal nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis (peri-mandibular)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early accrual closure due to manufacturer's limited drug supply.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Edwin Posadas, MD</name_or_title>
      <organization>Cedars-Sinai Medical Center</organization>
      <phone>310-423-7600</phone>
      <email>Edwin.Posadas@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

